报价延迟最少15分钟:2026/04/25 18:44 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.98 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.68/-1.41
|
|
企业价值
112.38M
|
| 资产负债 |
|
每股账面净值
1.44
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
35.58M
|
|
每股收益
0.50
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. |
